JAZZ
Jazz Pharmaceuticals plc
JAZZ's outlook is improving despite an expensive valuation.
OSCR
Oscar Health, Inc.
OSCR has the edge over JAZZ overall, supported by stronger modeled upside and lower modeled downside.
JAZZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Under pressure |
JAZZ's revenue, profitability and cash flow are currently healthy, but its balance sheet is under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
JAZZ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.1x | $240 | — |
| Cheap | 15x | $45.24 | -81% |
| Fair | 20x | $62.02 | -74% |
| Current | 78x | $240 | — |
| Expensive | 140x | $430 | +79% |
Historical ranges are pointers, not guarantees.
JAZZ's PE is in its expensive range at 78x. If earnings grow as analysts expect, today's price would be 9.1x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over JAZZ in the historical PE scenario, which offers more potential upside but is not a forecast.
JAZZ Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for JAZZ, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
JAZZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.33 | +758% |
| Q3 2026 | $3.07 | +$9.28 |
| Q2 2026 | $14.63 | +$21.50 |
| Q1 2026 | $0.11 | -99% |
| Q4 2025 | -$5.84 | -168% |
| Q3 2025 | -$6.21 | -188% |
| Q2 2025 | -$6.87 | -218% |
| Q1 2025 | $7.36 | +52% |
| Q4 2024 | $8.65 | +42% |
JAZZ has returned to profit: it earned $3.07 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
JAZZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +10% |
| Q2 2026 | $1.2B | +16% |
| Q1 2026 | $1.1B | +19% |
| Q4 2025 | $1.2B | +10% |
| Q3 2025 | $1.1B | +6.7% |
| Q2 2025 | $1B | +2.1% |
| Q1 2025 | $897.8M | -0.5% |
| Q4 2024 | $1.1B | +7.5% |
JAZZ's revenue has grown year over year for six quarters in a row: $1.2B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -33% | -38 points |
| Q2 2026 | 21% | +86 points |
| Q1 2026 | 31% | +38 points |
| Q4 2025 | 21% | +3.7 points |
| Q3 2025 | 5.1% | -20 points |
| Q2 2025 | -66% | -85 points |
| Q1 2025 | -6.2% | -14 points |
| Q4 2024 | 18% | +5.4 points |
JAZZ's operating margin was −33% last quarter, down 38 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over JAZZ on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over JAZZ on profitability, with a higher operating margin.
JAZZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $489.9M | +6.6% |
| Q2 2026 | $397.6M | +424% |
| Q1 2026 | $388.5M | -6.6% |
| Q4 2025 | $345.8M | -10% |
| Q3 2025 | $459.4M | +18% |
| Q2 2025 | $75.9M | -77% |
| Q1 2025 | $415.9M | +60% |
| Q4 2024 | $385.3M | +145% |
JAZZ's free cash flow has been positive every quarter for seven years: $1.6B over the past year, up 21% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over JAZZ on cash flow, with more consistent year-over-year improvement.
JAZZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -6.8% | -4.7M shares |
| 1 year | +5% | +3.1M shares |
| 3 years | -9.2% | -6.6M shares |
| 5 years | +5.6% | +3.4M shares |
| Available history | +12% | +7.2M shares |
JAZZ has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $225M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $150M |
| Q4 2023 | $99.8M |
| Q3 2023 | $74.4M |
| Q4 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
JAZZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 5.2x | High |
| Q4 2025 | 14.9x | High |
| Q3 2025 | 21.1x | High |
| Q2 2025 | 11.0x | High |
| Q1 2025 | 2.8x | Moderate |
| Q4 2024 | 2.7x | Moderate |
JAZZ's net debt is about 3.1 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over JAZZ on leverage, with a lower net debt burden relative to earnings.
JAZZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 43.8 | Neutral |
JAZZ's weekly RSI is 58 (neutral) and its Stochastic is 44 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
JAZZ PE vs Healthcare Sector
| Metric | JAZZ | Sector median | Relative |
|---|---|---|---|
| PE | 78x | 26x | 203% above |
| PE % | 81 | 29 | 52 pts above |
JAZZ is trading at 78x earnings, a 203% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over JAZZ on valuation relative to its sector.
JAZZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $225.9 | 6.4% above |
| 20 week MA | $239.1 | 0.5% above |
| 50 week MA | $211.0 | 14% above |
| 100 week MA | $167.5 | 43% above |
| 200 week MA | $146.0 | 65% above |
JAZZ is in an uptrend: it's above all five of its weekly moving averages, and 65% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
JAZZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $150.9 | $157.3 | +4.2% |
| 2021 | $157.3 | $128.2 | -18% |
| 2022 | $128.2 | $157.2 | +23% |
| 2023 | $157.2 | $123.0 | -22% |
| 2024 | $123.0 | $124.6 | +1.3% |
| 2025 | $124.6 | $170.5 | +37% |
| 2026 YTD | $170.5 | $240.4 | +41% |
JAZZ has finished higher in four of the last six years. It's up 41% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over JAZZ on returns for 2026, with the stronger performance.